May 13
Respirion offers hope for people living with cystic fibrosis
Read moreBrandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areVaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution
View ProjectDeveloping a new class of therapeutics that enhance the function of beneficial proteins
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectThe Florey Institute of Neuroscience and Mental Health is one of the largest and highly respected brain research centres in the world.
ViewThe Burnet Institute is an independent, not‐for‐profit Australian organization that is unique in its approach of linking medical research with public health action to address many of the major health problems affecting disadvantaged communities. This approach allows us to develop innovative health solutions ranging from the highly technological through to those that are community-based.
ViewThe George Institute for Global Health is a not-for-profit global medical research institute established and headquartered in Sydney, with major centres in China, India and the UK, and an international network of experts and collaborators.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreFunding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential
Read moreENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator
Read morePathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Read more